ДОЛТОН Джеймс Т.,СТЕЙНЕР Митчелл С.,КОСС Кристофер С.
申请号：
RU2014111060
公开号：
RU2014111060A
申请日:
2012.08.23
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating, suppressing, reducing the incidence of, reducing the severity or inhibit progression castrate-resistant prostate cancer (KRRPZH) and its symptoms or improve survival in men with castrate-resistant prostate cancer comprising administering a therapeutically effective amount of a compound of formula I or its isomer, pharmaceutically acceptable salt, pharmaceutical product, polymorph, hydrate or any combination thereof: wherein = Y is C (O) or CH R, independent Ryavlyayutsya mo hydrogen, halogen, hydroxyl, alkoxy, cyano, nitro, CF, N (R), a sulfonamide, SOR, alkyl, haloalkyl, aryl, O-Alk-NRRili O-Alk-heterocycle, wherein the heterocycle is a 3-7 membered a substituted or unsubstituted heterocyclic ring, optionally aromatic R, Ryavlyayutsya independently hydrogen, halo, hydroxyalkyl, hydroxy, alkoxy, cyano, nitro, CF, NHCOR, N (R), a sulfonamide, SOR, alkyl, haloalkyl, aryl, or protected hydroxyl R is alkyl, hydrogen, haloalkyl, digaloalkilom, trigaloalkilom, CHF, CHF, CF, CFCF, aryl, phenyl ohm, halogen, alkenyl, CN, NOili OH r and Ryavlyayutsya independently hydrogen, phenyl, an alkyl group of 1 to 6 carbon atoms, 3-7 membered cycloalkyl, 3-7-membered heterocyclic ring, 5-7 membered aryl or R Robrazuyut 3-7 membered ring with the nitrogen atom j and k are independently 1-4 iAlk is linear alkyl of 1-7 carbons, branched alkyl of 1-7 carbons or cyclic alkyl of 3-8 uglerodov.2. A method according to claim 1, characterized in that said compound of formula I is selected from:. 3. The method of claim. 1, characterized in that said compound of formula I yavlyaets1. Способ лечения, супрессии, снижения частоты возникновения, снижения степени тяжести или ингибирования прогрессирования кастрационно-резистентного рака предстательной железы (КРРПЖ) и его симптомов или повышения выживаемости у мужчин с кастрационно-резистентным раком предстательной железы, включающий введение терапевтически эффективного количества соединения формулы I или его изомера, фармаце
